Other solid tumor probes
Poseidon

Click on Product Name for more information
Click on Catalog# for Application Manual

Product Name Color Catalog#
ON= Oncology probes 10 test, ready-to-use format

Other Solid Tumors

ON EGFR, Her-1 (7p11) / SE 7  red/green  KBI-10702 
ON CC hTERT (3q26) / C-MYC (8q24) / SE 7 TC  red/green/blue  KBI-10704 
ON MYCN (2p24) / LAF (2q11) red/green  KBI-10706 
ON PPARy (3p25) Break  red/green  KBI-10707 
ON EWSR1 (22q12) Break  red/green  KBI-10708 
ON hTERT (5p15) / 5q31 (tissue) red/green  KBI-10709 
ON p16 (9p21) / 9q21 (tissue) red/green  KBI-10710 
ON MLL (11q23) / SE 11  red/green  KBI-10711 
ON SRD (1p36) / SE 1(1qh) red/green  KBI-10712 
ON SYT (18q11) Break  red/green  KBI-10713 
ON CHOP (12q13) Break  red/green  KBI-10714 
ON FUS (16p11) Break red/green KBI-10715
ON FKHR (13q14) Break red/green KBI-10716
ON MDM2 (12q15) / SE 12 red/green KBI-10717
ON PTEN (10q23) / SE10 red/green KBI-10718
ON C-MET (7q31) / SE 7 red/green KBI-10719
ON AURKA (20q13) / 20q11 red/green KBI-10721
ON AURKB (17p13) / SE 17 red/green KBI-10722
ON TOP2A (17q21) / SE 17 red/green KBI-10724
ON CDK4 (12q13) / SE 12 red/green KBI-10725
ON TMPRSS2-ERG (21q22) Del, Break, TC red/green/blue KBI-10726
ON IGH (14q32) Break (tissue) red/green KBI-10729
ON BCL-6 (3q27) Break (tissue) red/green KBI-10730
ON MALT (18q21) Break (tissue) red/green KBI-10731
ON ZNF217 (20q13) / 20q11 red/green KBI-10733
ON CCND1 (11q13), SE 11 red/green KBI-10734
ON TOP2A (17q21) / Her2 (17q12) / SE 17 TC red/green/blue KBI-10735
ON MDM4 (1q32) / SE1 red/green KBI-10736
ON FGFR1 (8p12), Break red/green KBI-10737
ON p53 (17p13) / SE 17 (tissue) red/green KBI-10738
ON ERCC1 (19q13) / ZNF443 (19p13) New!  red/green KBI-10739
ON TFE3 (Xp11) Break New! red/green KBI-10741

 

Poseidon

Click on Product Name for more information
Click on Catalog# for Application Manual

Product Name Color Catalog#
ON= Oncology probes 10 test, ready-to-use format

Other Solid Tumors

ON EGFR, Her-1 (7p11) / SE 7  red/green  KBI-10702 
ON CC hTERT (3q26) / C-MYC (8q24) / SE 7 TC  red/green/blue  KBI-10704 
ON MYCN (2p24) / LAF (2q11) red/green  KBI-10706 
ON PPARy (3p25) Break  red/green  KBI-10707 
ON EWSR1 (22q12) Break  red/green  KBI-10708 
ON hTERT (5p15) / 5q31 (tissue) red/green  KBI-10709 
ON p16 (9p21) / 9q21 (tissue) red/green  KBI-10710 
ON MLL (11q23) / SE 11  red/green  KBI-10711 
ON SRD (1p36) / SE 1(1qh) red/green  KBI-10712 
ON SYT (18q11) Break  red/green  KBI-10713 
ON CHOP (12q13) Break  red/green  KBI-10714 
ON FUS (16p11) Break red/green KBI-10715
ON FKHR (13q14) Break red/green KBI-10716
ON MDM2 (12q15) / SE 12 red/green KBI-10717
ON PTEN (10q23) / SE10 red/green KBI-10718
ON C-MET (7q31) / SE 7 red/green KBI-10719
ON AURKA (20q13) / 20q11 red/green KBI-10721
ON AURKB (17p13) / SE 17 red/green KBI-10722
ON TOP2A (17q21) / SE 17 red/green KBI-10724
ON CDK4 (12q13) / SE 12 red/green KBI-10725
ON TMPRSS2-ERG (21q22) Del, Break, TC red/green/blue KBI-10726
ON IGH (14q32) Break (tissue) red/green KBI-10729
ON BCL-6 (3q27) Break (tissue) red/green KBI-10730
ON MALT (18q21) Break (tissue) red/green KBI-10731
ON ZNF217 (20q13) / 20q11 red/green KBI-10733
ON CCND1 (11q13), SE 11 red/green KBI-10734
ON TOP2A (17q21) / Her2 (17q12) / SE 17 TC red/green/blue KBI-10735
ON MDM4 (1q32) / SE1 red/green KBI-10736
ON FGFR1 (8p12), Break red/green KBI-10737
ON p53 (17p13) / SE 17 (tissue) red/green KBI-10738
ON ERCC1 (19q13) / ZNF443 (19p13) New!  red/green KBI-10739
ON TFE3 (Xp11) Break New! red/green KBI-10741

 

   
Other Solid Tumors Probes Minimize

In solid tumors significantly high levels of chromosome abnormalities have been detected, but distinction between significant and irrelevant events has been a major challenge. Consequently, the application of cytogenetic technology as diagnostic, prognostic, or therapeutic tools for these malignancies has remained largely underappreciated. The emergence of FISH is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer diagnosis, prognosis, and therapy selection, alone or with other diagnostic methods.

[Back to top]

In solid tumors significantly high levels of chromosome abnormalities have been detected, but distinction between significant and irrelevant events has been a major challenge. Consequently, the application of cytogenetic technology as diagnostic, prognostic, or therapeutic tools for these malignancies has remained largely underappreciated. The emergence of FISH is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer diagnosis, prognosis, and therapy selection, alone or with other diagnostic methods.

[Back to top]